A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with newly Diagnosed Diffuse Large B-cell Lymphoma
Individuals aged 65 years or older who are intolerant to chemotherapy, regardless of gender;
ECOG 0-1； IPI score ≤ 3 points;
Expected survival period of more than 3 months;
DLBCL diagnosed by tissue biopsy pathology;
Clear patients with neurological or psychiatric disorders, including dementia or seizures, a history of abuse of psychotropic drugs that cannot be quit, or other substantial lesions that may increase central neurotoxicity;
Individuals who are currently participating in other clinical trials or have participated in other clinical studies within the first 4 weeks of enrollment (excluding those who have not received treatment);
Systemic autoimmune diseases or immunodeficiency;
Refusing to collect blood samples;
Mingzhi Zhang
Lead sponsor
Zhengzhou University
Sponsor institution